Lipocine Inc. is a Lipocine Inc is a clinical-stage biopharmaceutical company. It is focused on oral drug delivery technology for the development of pharmaceutical products focusing on metabolic and endocrine disorders.
Lipocine Inc. (LPCN) had a rough trading day for Tuesday January 26 as shares tumbled 10%, or a loss of $-0.22 per share, to close at $1.98. After opening the day at $1.90, shares of Lipocine Inc. traded as high as $2.04 and as low as $1.80. Volume was 26.85 million shares over 73,207 trades, against an average daily volume of n/a shares and a total float of 65.69 million.
As a result of the decline, Lipocine Inc. now has a market cap of $130.06 million. In the last year, shares of Lipocine Inc. have traded between a range of $2.43 and $0.31, and its 50-day SMA is currently $n/a and 200-day SMA is $n/a.
Lipocine Inc is a clinical-stage biopharmaceutical company. It is focused on oral drug delivery technology for the development of pharmaceutical products focusing on metabolic and endocrine disorders. The company’s product TLANDO, is an oral testosterone replacement therapy (“TRT”). It also has other products in the pipeline such as LPCN 1144, LPCN 1148 and LPCN 1107.
Lipocine Inc. is based out of Salt Lake City, UT and has some 12 employees. Its CEO is Mahesh V. Patel.